anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To prepare an antiaging agent, comprising an extract from a specific plant as an active ingredient and capable of manifesting excellent inhibiting actions on elastases and recovering and maintaining tensity and elasticity of skin, thereby preventing the skin from aging and maintaining a state of the youthful skin. SOLUTION: This antiaging agent comprises an extract from a plant belonging to the genus Caesalpinia therein. Secang (botanical name: Caesalpinia sappan) is especially preferred as the plant belonging to the genus Caesalpinia. The antiaging agent is especially useful as an inhibitor of elastases and a cosmetic for preventing aging. The amount of the blended extract of the plant belonging to the genus Caesalpinia is 0.0005-20.0wt.%, preferably 0.001-10.0wt.% expressed in terms of a dry substance in the total amount of the antiaging agent. The antiaging agent can be utilized as a cosmetic for a makeup cosmetic and a toiletry product.
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with mirtazapine tablets and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions” is available for mirtazapine. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking mirtazapine.
MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
The beneficial effects of soluble dietary fiber to health are well known: many studies show clearly that it delays the onset of cardiovascular disease and some cancers, and improves glycemic control in type 2 diabetes. (1,2). Overweight and obesity are known to be associated with increased rate of diabetes, hypertension and cardiovascular diseases, as well as to colon and breast cancer. The introduction of 25-30gr of dietary fiber daily would therefore indicated not only in type 2 diabetic subjects, but also in obese and overweight patients. Most of the foods commonly consumed in Western countries are low in dietary fiber: to reach the recommended levels people should introduce whole grain cereals, legumes, vegetables and dried fruits, not always accepted. We tested the effects on health of crackers baked with a special Integralbianco® flour, enriched with 3,2g of Arabinoxylan / 100g (vs refined flour).
Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
[Problem] The objective of the present invention is to provide an anticancer agent for stopping the division of cancer cells. [Solution] The present invention provides an anticancer agent that, for a case in which an acid will be added, is an acid solute. The enzyme ASB7, which causes cancer cell division, has an optimal pH, and therefore if the pH value inside cancer cells is caused to deviate from the optimal pH value, the enzyme no longer functions. Thus, if cancer cells are made to be acidic by adding an acid to the cancer cells for the purpose of changing the hydrogen ion concentration inside the cancer cells, the pH inside the cancer cells changes and deviates from the optimal pH value, and therefore the enzyme ASB7 that causes cancer cells to divide no longer functions, whereby the division of cancer cells is stopped. The present invention provides an anticancer agent that, for a case in which a base will be added, is a base solute. The enzyme ASB7, which causes cancer cell division, has an optimal pH, and therefore if the pH value inside cancer cells is caused to deviate from the optimal pH value, the enzyme no longer functions. Thus, if cancer cells are made to be basic by adding a base to the cancer cells for the purpose of changing the hydrogen ion concentration inside the cancer cells, the pH inside the cancer cells changes and deviates from the optimal pH value, and therefore the enzyme ASB7 that causes cancer cells to divide no longer functions, whereby the division of cancer cells is stopped.
Improved metabolic control reduces both the onset and progression of diabetes-related complications in adults and adolescents with type 1 diabetes. Frequency of contact with the medical care team has been associated with better control. Both the American Diabetes Association and Canadian Diabetes Association recommend regular quarterly visits. However, the increase in case loads and the limited manpower available forces us to look at alternative models of care. A model of care in which medical visits alternate between a face to face multidisciplinary visits and a virtual visit done via fax or e-mail communication and a phone call may be advantageous to both the patient and the medical care team. For the patient and his family, this model would decrease time away from school and work, travel inconveniences and costs. For the medical care team it may decrease time per patient and therefore increase the number of patients served with the same resources.
Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity − A 10 to 20 mm increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of patients have had increased premature ventricular beats during infusions. These effects are dose related. 

Hypotension − Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate. 

Reactions at Sites of Intravenous Infusion − Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Isolated cases of cutaneous necrosis (destruction of skin tissue) have been reported. 

Miscellaneous Uncommon Effects − The following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations and shortness of breath. Isolated cases of thrombocytopenia have been reported. 

Administration of dobutamine hydrochloride, like other catecholamines, can produce a mild reduction in serum potassium concentration, rarely to hypokalemic levels (see PRECAUTIONS).
A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mg/m2/day).

No increase in drug related neoplasms was noted when compared to control.

The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.

A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).
PURPOSE:An antilipemic agent, containing a specific furyloxazolylacetic acid derivative or a salt thereof as an active constituent, and having improved serum chlolesterol and serum triglyceride lowering action with little side effects such as hepatic dysfunction. CONSTITUTION:An antilipemic agent containing a compound of formula I (R<1> is lower alkyl; R<2> and R<3> are H or lower alkyl; ring A is phenyl or halogenophenyl as an active constituent. The compound of formula I has improved serum cholesterol and serum triglyceride lowering action and further inhibitory action on platelet agglutination and is a compound useful as the antilipemic agent. The compound of formula I has low toxicity and high safety. The preferred oral dose thereof is 5-20mg/kg/day. The compound of formula I is obtained by alkylating a compound of formula II (R<4> is lower alkyl).
Participants prescribed standard of Care (SoC) only. Patients can be treated with maximum tolerated dose of statins and/or with add-on therapy with ezetimibe, PCSK9 inhibitors (alirocumab or evolocumab), fibrates, bempedoic acid or bile acid sequestrants, but not inclisiran.
PURPOSE: To obtain a cosmetic having excellent hair nourish-accelerating action, wet-keeping action and subcutaneous blood flow-increasing action, etc., by including a cultured material derived from an action of a specific bacterium to a liquid hydrocarbon as a raw material in a specific condition as an active component. CONSTITUTION: A liquid hydrocarbon is used as a raw material and a bacterium having an ability of producing oils and fats affecting the liquid hydrocarbon is affected to the hydrocarbon, and the resultant oils and fats are contained as active components in the aimed cosmetic suitable for hair-nourishing and skin, etc. The bacterium belongs to genus Mycobacterium, genus Brevibacterium or genus Arthrobacter. Concretely, a new 0-201 strain of genus Mycobacterium (FERM-P-14532) is preferable. The oils and fats are preferably extracted from endo-biomass by an organic solvent. Furthermore, before the extraction by the organic solvent, the biomass is preferably performed an enzyme treatment and/or mechanical treatment. This cosmetic is used as a hair-nourishing agent, a hair cream, a hair tonic, a shampoo or a skin cream, etc.
Prospective, double-blind, randomized clinical study with enrollment of patients over at least 18 years of age who require coronary angiography for a clinical indication with hypertension defined as systolic blood pressure \>140mmHg or diastolic blood pressure \>90mmHg. Inclusion requires at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis \>50% without any evidence of inducible ischemia. The target vessel for IVUS interrogation must not have undergone angioplasty (deferred lesion) nor have more than 50% luminal narrowing throughout a target segment. Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 (Fimasartan 60-120 mg vs placebo). All subjects will be followed up at 1 year for serial VH-IVUS and conventional IVUS evaluation. Also, OCT sub-study will be performed in selected patients with lesions at least 20 mm distally located from coronary ostium. All patients will be blindly assigned to control and Fimasartan once daily as 1:1 ratio and are prescribed for 1year.
New agents for combatting snoring contain (A) a surface-active substance, (B) a preservative and/or a substance having a bactericidal or fungicidal action on the mucous membranes, and (C) a substance which renders the mucous membranes supple, in (D) physiological saline, opt. together with (E) further additives tolerated by the mucous membranes. Preferred surface active agents are sorbitan polyoxyethylene esters, esp. polyoxyethylene sorbitan monooleate. Preferred preservatives are ethanol, p-hydroxybenzoic acid esters, 2-phenoxyethanol, benzoic acid and its salts, and sorbic acid and its esters. Pref. mucous membrane disinfectants are benzalkonium chloride and chlorobutanol. Preferred substances rendering the mucous membranes supple are glycerol and panthenol. Suitable further additives are vitamin A, vitamin E, hydrolases, lipases and proteases. The surface active substance is pref. present in a concn. of 0.1-0.5 wt.%. Agents for intranasal application to prevent or reduce snoring. The agents act by maintaining the nose and throat membranes in a moist, smooth state and removing irregularities and dryness caused by environmental influences.
Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who currently qualify for medically tailored meals (MTMs). This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period.
Electroconvulsive therapy (ECT) is one of the most robust antidepressant treatments available. However, there is the potential for significant acute and longer term adverse cognitive effects with ECT and the antidepressant response requires multiple treatment sessions, increasing risk of adverse effects. Further, antidepressant response to ECT is often less than maximal and relapse is common. Growing preclinical and clinical evidence of the rapid-acting antidepressant properties of the anesthetic agent ketamine suggests the use of ketamine anesthesia as a strategy to increase rate of response and shorten treatment course in the administration of ECT. In addition, preclinical and clinical evidence suggests the potential of ketamine to decrease the adverse cognitive effects associated with ECT.

The investigators propose a pilot study to measure both acute therapeutic efficacy and cognitive side effects of ECT using ketamine compared to methohexital in depressed patients. The investigators will also explore other parameters of ECT such as seizure duration and morphology, as well as hemodynamic and behavioral changes.
BACKGROUND: In significant events like chemical, biological, radiological, nuclear, and explosive (CBRNE) incidents, additional expertise in specific chemical substances becomes essential. Train-the-trainer programmes are used to increase knowledge and skills in a variety of fields and have been shown to be a cost-effective training method, eliminating the necessity of bringing in external experts or requiring participants to travel outside their region. Care in Hazardous Environments (CiHE) is one example of a course which comprises basic multi-disciplinary training together with personnel from rescue, police, and emergency medical services to prepare them to handle chemical and radioactive nuclear incidents. The train-the-trainer programme described in this study contains both theoretical and practical components, intended for instructors who will lead training on CiHE incidents. This study aimed to evaluate trainers' level of knowledge before and after a train-the-trainer programme, as well as their thoughts about becoming an instructor i.e. the pedagogical competence for the Care in Hazardous Environments course.
METHODS: A pre- and post-test, along with an evaluation of open-ended response options were employed to assess the effectiveness of the train-the-trainer programme for teaching the basic course (CiHE). A total of 49 participants were enrolled in the programme.
RESULTS: Participants showed significant improvement in chemical, radiological and nuclear (CRN) response knowledge in two of the eight questions between the pre- and post-tests. The two questions that improved pertained to chemical substances and basic principles of radiation protection. Instructors trained in the train-the-trainer programme are intended to bring new knowledge, incorporate a rarely discussed topic into instruction regularly, and de-stigmatise CRN incidents by helping raise the minimum competency levels in their respective organisation.
CONCLUSION: An effective response to CBRNE events begins with readiness. First responders must be prepared and possess knowledge of both CRN components as well as protective gear to keep themselves and others safe at the incident scene. This study shows the importance of the train-the-trainer programme in continuing to educate police, and personnel from rescue and emergency medical services in CiHE, enable them to collaboratively prepare to handle CRN incidents.
Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
Patients randomized to digital health intervention group will receive standard care plus the Elfie solution. Participants randomized to the Elfie solution will be instructed to download the Elfie app and will receive training on how to register in the app and on how to use all the app features. Participants will be then instructed to use the app according to the monitoring plan created by the app for the following 6 months.
Three recorded semi-structured video interviews will be conducted with each interventionist. One will occur immediately after training; this will focus on their sense of the completeness and adequacy of the training program, including the training methods, videos, and materials, and their perceived readiness to lead the program. Another interview will be done immediately after the conduct of each of the two Savvy programs they lead, asking them to report on their own performance as interventionists, including any adaptation processes in which they might have engaged, and to reflect on ways the training might be improved to strengthen their skills, including for adaptation. In total: 18 interviews.
PURPOSE: The aim was to longitudinally explore changes in fatigue- and cognition-related symptoms during the first year after hospital treatment for COVID-19.
METHOD: Patients hospitalized for COVID-19 in Gothenburg, Sweden, were consecutively included from 01-07-2020 to 28-02-2021. Patients were assessed at the hospital (acute) and at 3 and 12 months after hospital discharge. Cognition was assessed with the Montreal Cognitive Assessment (MoCA), the Trail Making Test B (TMTB), and the Cognitive Failure Questionnaire (CFQ). Fatigue was assessed using the Multidimensional Fatigue Inventory-20 (MFI-20) and the Mental Fatigue Scale (MFS). Data was analyzed with demographics and changes over time calculated with univariable mixed-effects models.
RESULT: In total, 122 participants were included. Analyzes of Z-scores for MoCA indicated improvement over the year, however the results were 1 SD below norm at all assessments. Alertness (TMTB scores) improved significantly from the acute assessment to the 12- month follow-up (p = <0.001, 95% CI 34.67-69.67). CFQ scores indicated cognitive impairment, and the sum scores for MFI reflected a relatively high degree of fatigue at follow-up.
CONCLUSION: In the first year after hospitalization for COVID-19, most patients experienced fatigue and cognitive impairment. Alertness improved, but improvements in other domains were limited.
PCT No. PCT/HU84/00006 Sec. 371 Date Aug. 27, 1984 Sec. 102(e) Date Aug. 27, 1984 PCT Filed Jan. 25, 1984 PCT Pub. No. WO84/02843 PCT Pub. Date Aug. 2, 1984.The invention relates to a process for the preparation of sustained release solid pharmaceutical compositions having an active ingredient content of at least 80% and possessing a structure which loosens in aqueous medium but does not disintegrate to discrete particles within 4 hours which comprises coating the particles of the active ingredient in a liquid medium with a water insoluble polymer-preferably with an ethyl cellulose polymer film-and thereafter admixing the coated crystals with at least one disintegrating agent being capable of swelling in aqueous medium and other auxiliary agents conventionally used in pharmaceutical industry and pressing the mixture into tablets. The advantage of the process of the present invention is that it is readily feasible with a very wide range of active ingredients and provides sustained release tablets having a high active ingredient content.
This invention provides chimeric DNA/RNA catalytic molecules useful to cleave RNA sequences. The invention specifically provides two different chimeric DNA-RNA-DNA-RNA-DNA catalytic molecules which are targeted to cleave HIV-1 RNA sequences. These chimeric molecules include DNA sequences which flank a catalytic RNA center. Interaction with the HIV-1 substrate RNA is achieved by Watson-Crick base pairing of the DNA flanking sequences with HIV-1 RNA. The catalytic ribonucleotide center cleaves the phosphodiester bond of the substrate HIV-1 RNA at the expected location. <IMAGE>
Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
The invention discloses a spraying agent for removing liver stink of hepatic-failure patients and a preparation method. The spraying agent is prepared from the following bulk drugs: radix scutellariae, calculus bovis, forsythia suspensa, flos lonicerae, benzoinum, cablin potchouli herb, herba eupatorii, gypsum fibrosum, rhizoma coptidis, fructus gardeniae, semen coicis, mentha haplocalyx Briq., herba artemisiae annuae, radix curcumae, rhizoma imperatae and common cephalanoplos herb. After being applied for local treatment, the spraying agent is capable of removing oral cavity peculiar smell of a hepatic-failure patient and keeping oral cavity refreshing for a relatively long time, and helps to effectively inhibit oral-cavity bacteria and fungi propagation of the patient and reduce oral cavity infection. The traditional Chinese medicine spraying agent is low in price, and simple and practicable in operation. The spraying agent can be regularly applied to clean oral cavity and maintain oral cavity normal flora. The spraying liquid volume is less and constant at every time, mistaken aspiration is prevented, and the patient safety is guaranteed.